Therapeutics News and Research

RSS

Exelixis files new drug application for a proprietary novel anticancer compound

Exelixis, Inc. has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for XL999, a proprietary novel anticancer compound.

29 Jun 2004

Stimulation or drugs that target the pro-opiomelanocortin system will be effective in treating diabetes or obesity

There’s more than one way to slim a cat - at least that’s the hope of University of Florida obesity researchers, who believe pets and even people may someday benefit from gene therapy research aimed at breaking through the biochemical bottleneck that makes many middle-aged mammals gain weight.

17 Jun 2004

New Cincinnati adult diabetes center

The Diabetes Center at the University of Cincinnati is a joint effort by UC and community leaders to improve diabetes care in the region and open the door to more community programs addressing the health care needs of people with diabetes.

15 Jun 2004

Drug combination reduces cocaine use

Researchers at the Yerkes National Primate Research Center are the first to demonstrate that a combination of drug therapies targeting the region of the brain that controls drug abuse and addiction significantly reduces cocaine use in nonhuman primates.

15 Jun 2004

SARS siRNA studied further to help many respiratory diseases including lung cancer

Intradigm Corporation, has announced achievement of prophylactic and therapeutic effects of siRNA (small interfering RNA) inhibitors of SARS-CoV in non-human primate cells. The results are published in the June 2004 issue of Antiviral Therapy (International Medical Press).

15 Jun 2004

Real-Time Immuno-PCR has the ability to detect HIV infection earlier than all current methods

Researchers at the Institute of Human Virology have developed an ultra-sensitive testing technique that has shown the ability to detect HIV infection earlier than all current methods.

15 Jun 2004

University of Cambridge to generate antibodies

The University of Cambridge has announced a licensing agreement with Human-Human Hybridoma, Inc. (3H) to exploit a human myeloma cell line (Karpas-707H) that can be used in research and for the production of human monoclonal antibodies.

15 Jun 2004

Conflicting views on embryonic and adult stem cells complicate research in stem cell therapeutics

Though there has been considerable biological and political debate over the use of embryonic stem cells (ESCs) vs. adult stem cells (ASCs) as therapies for tissue engineering and organ transplants, inherent benefits and drawbacks in both techniques compel them to coexist and complement each other.

10 Jun 2004

Project aimed at eliminating anthrax as a potential weapon for terrorists

La Trobe University scientists are using their own unique peptide 'library' containing a thousand million molecular sequences in a project aimed at eliminating anthrax as a potential weapon for terrorists.

10 Jun 2004

A biological agent used without chemotherapy appears to offer a disease-free future to patients with rare leukemia

A biological agent — a drug that wraps vitamin A inside bubbles of fat — used without chemotherapy appears to offer as many as one-third of patients with a rare form of leukemia an opportunity for a long-term, disease-free future, say researchers at The University of Texas M. D. Anderson Cancer Center.

7 Jun 2004

200 new therapies are being developed for prostate cancer

The Prostate Cancer Foundation (PCF) has announced that more than 200 new therapies are being developed for prostate cancer, many by researchers supported by the PCF. Substantially more prostate cancer therapies are in later stages of clinical development (Phases II and III) than ever before.

5 Jun 2004

New medical patent covering the generation of genetically enhanced therapeutic antigens

Morphotek, Inc. announced today the issuance of United States Patent 6,737,268 covering the generation of genetically enhanced therapeutic antigens.

2 Jun 2004

36 percent of Americans are using complementary and alternative medicines

A new, comprehensive government survey, released by the National Center for Complementary and Alternative Medicine (NCCAM), reveals that 36 percent of Americans are incorporating complementary and alternative medicines (CAM) into their health care regimen.

1 Jun 2004

New company is developing advanced therapeutics for stroke victims

Arizona Engineered Therapeutics Inc., a new company based on the research of three Arizona State University professors, is moving its first drug candidate closer to clinical trials.

26 May 2004

Specialists work to overcome Huntington's disease

The Huntington's Disease Society of America (HDSA) recognizes the Huntington's Disease Clinic and Research Group at University of Iowa Hospitals and Clinics as one of only 17 national Huntington's Disease Centers of Excellence.

25 May 2004

Speakers will predict the future of where the field of cancer diagnosis and treatment is going in the next ten years

Nexxus, the West of Scotland Bioscience Network will hold the second event of the Horizons in Biomedicine Series today at 6.30pm at the Glasgow Science Centre.

25 May 2004

Combination drug therapies targeting brain region that controls addiction significantly reduces cocaine use in primates

Researchers at the Yerkes National Primate Research Center of Emory University are the first to demonstrate a combination of drug therapies targeting the region of the brain that controls drug abuse and addiction significantly reduces cocaine use in nonhuman primates.

24 May 2004

Cystic Fibrosis Foundation Therapeutics awards $21 million to Vertex

Vertex Pharmaceuticals Incorporated has announced that it has expanded its drug discovery and development collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation.

24 May 2004

An antibiotic, Tigecycline produces 74 percent cure rate in cSSSI patients

An antibiotic, currently being tested in clinical trials, produced a 74 percent cure rate for hospitalized patients with possibly life-threatening, complicated skin and skin structure infections (cSSSI).

23 May 2004

Protein that appears to play a key role in Alzheimer's disease

A protein that allows human cancer to resist multiple anticancer drugs also appears to play a key role in Alzheimer's disease, according to research conducted at Fox Chase Cancer Center. The protein, active in brain tissue, could be a target for new drugs to treat patients with Alzheimer's.

20 May 2004

Therapeutics News and Research

Exelixis files new drug application for a proprietary novel anticancer compound

Stimulation or drugs that target the pro-opiomelanocortin system will be effective in treating diabetes or obesity

New Cincinnati adult diabetes center

Drug combination reduces cocaine use

SARS siRNA studied further to help many respiratory diseases including lung cancer

Real-Time Immuno-PCR has the ability to detect HIV infection earlier than all current methods

University of Cambridge to generate antibodies

Conflicting views on embryonic and adult stem cells complicate research in stem cell therapeutics

Project aimed at eliminating anthrax as a potential weapon for terrorists

A biological agent used without chemotherapy appears to offer a disease-free future to patients with rare leukemia

200 new therapies are being developed for prostate cancer

New medical patent covering the generation of genetically enhanced therapeutic antigens

36 percent of Americans are using complementary and alternative medicines

New company is developing advanced therapeutics for stroke victims

Specialists work to overcome Huntington's disease

Speakers will predict the future of where the field of cancer diagnosis and treatment is going in the next ten years

Combination drug therapies targeting brain region that controls addiction significantly reduces cocaine use in primates

Cystic Fibrosis Foundation Therapeutics awards $21 million to Vertex

An antibiotic, Tigecycline produces 74 percent cure rate in cSSSI patients

Protein that appears to play a key role in Alzheimer's disease

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News